Abiomed Inc (ABMD)

Designed to Enable Ease of Use in High-Risk Percutaneous Coronary Interventions and in the ICU

Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts

First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program

Circulation Research paper supports previously published randomized clinical trial data

This patient-monitoring device-maker has plenty of room for growth.

Milestone Highlights Significant Unmet Need for Treatment Options Among Advanced Heart Failure Patients

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:

Leader in heart recovery technology highlights stories of women whose health and quality of life have been improved by Impella® heart pump

Largest Quarterly Sequential Revenue Increase in Company History

Largest Quarterly Sequential Revenue Increase in Company History

Impella 2.5, CP and 5.0 Only FDA Approved Percutaneous Heart Pumps Deemed Safe and Effective

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DLR, ESXB, IART, NMR, PBIB, PLNT, SANW, TCK Downgrades: AAN, ABMD, AXTA, CMC, CMPR, CVI, CVRR, DSPG, EHTH, ESSA, FCFS, NPTN, NWS, UHT, VDSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Study Evaluates the Safety and Feasibility of Unloading of the Left Ventricle with Impella CP® in STEMI Patients, without Cardiogenic Shock

Abiomed is Committed to Improving Outcomes in Protected PCI and Cardiogenic Shock

First ever percutaneous heart pump approval in Japan

Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate

Lower end of revenue guidance increased for FY 2017

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.